Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on donor-derived allogeneic cell-based immunotherapies for cancers. As a foreign private issuer, CytoMed reports primarily on Form 6-K, along with other applicable forms, to disclose material information to investors.
In these filings, readers can find press releases furnished as exhibits that detail clinical milestones, such as progress in the ANGELICA Phase I CAR gamma delta T cell trial in Singapore, memoranda of understanding for first-in-human γδ T cell trials in Malaysia, and collaborative research publications with The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia. Filings also cover interim and annual financial statements, management’s discussion and analysis of financial condition and results of operations, and information on at-the-market equity programs.
CytoMed’s SEC reports additionally describe corporate and strategic actions, including the acquisition of synergistic T cell technology assets, the purchase of a licensed cord blood bank in Malaysia, the creation of its cord blood-derived biotech platform under subsidiary LongevityBank, and changes in executive shareholdings. These documents offer insight into how the company funds and structures its gamma delta T cell, iPSC-derived hybrid cell, and cord blood-derived initiatives.
On Stock Titan, investors can access CytoMed’s latest SEC submissions as they are made available from EDGAR and use AI-powered summaries to interpret lengthy exhibits and financial sections. This helps clarify the implications of each 6-K, financial update, or transaction-related disclosure for GDTC’s clinical programs, regional expansion and capital strategy.
CytoMed Therapeutics Limited, a Singapore-based clinical stage cell therapy company, provided a new year update on its pipeline, funding and shareholder engagement. The company is advancing donor-derived gamma delta T cell and Natural Killer cell immunotherapies, including support from Enterprise Singapore for its Natural Killer cell work through subsidiary LongevityBank. Management believes it has enough resources to fund activities for at least a year and is exploring licensing, real estate asset monetisation and strategic partnerships to support the business with less dilution.
CytoMed highlighted a Memorandum of Understanding with Universiti Malaya to run a first-in-human Phase I trial of its allogeneic unmodified gamma delta T cells in no-option cancer patients in Malaysia, targeting an Investigational New Drug submission before June. This complements an ongoing Phase I CAR-T trial in Singapore, where six patients have been treated. The company also cited a recent co-authored preclinical publication with MD Anderson Cancer Center on acute myeloid leukemia and noted that its chairman intends to increase his shareholding. CytoMed is seeking shareholder feedback on a proposed scheme allowing shareholders, subject to medical approval and local rules, to use their shareholdings to access its donor-derived allogeneic unmodified gamma delta T cell therapy.
CytoMed Therapeutics Limited reported that it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia. The parties plan to explore a multi-site, first-in-human Phase I clinical trial of CytoMed’s patented donor-derived gamma delta T cell product candidate.
The proposed trial would focus on cancer patients who have exhausted standard treatment options and would evaluate both the safety and efficacy of using gamma delta T cells sourced from healthy donors. This represents an early clinical step for CytoMed’s off-the-shelf allogeneic cell therapy approach in Malaysia.
CytoMed Therapeutics Limited reported that it has completed the acquisition of synergistic assets from TC BioPharm Limited. These T cell technology assets are intended to be enhanced and re-purposed to treat cancers in China and India, signaling a focus on cell-based cancer therapies in large Asian markets. The announcement was made through a press release dated November 18, 2025, which is attached as an exhibit to this Form 6-K.
CytoMed Therapeutics Limited furnished a Form 6-K noting it issued a press release on November 6, 2025. The update announces a non-dilutive investment for its subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd and provides updates on its new China strategy.
The press release is included as Exhibit 99.1 titled “CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy.”
CytoMed Therapeutics Limited reported that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his shareholding through recent open‑market purchases of 105,824 shares.
According to the accompanying press release title, his effective ownership is now 21.95%. The update was furnished on a Form 6‑K dated October 22, 2025.
CytoMed Therapeutics Limited reported that it has submitted a cash bid of an undisclosed sum for a potential acquisition of selected, potentially synergistic assets of TC BioPharm Limited. The announcement was made on October 14, 2025, and notes that TC BioPharm entered administration on October 2, 2025.
The update signals an interest in expanding CytoMed’s capabilities through asset acquisition, though terms and valuation were not disclosed. A related press release is furnished as Exhibit 99.1. As this is a bid for assets rather than a completed transaction, outcomes and financial effects depend on subsequent developments and any negotiated terms.
CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CytoMed Therapeutics Limited reported that it has successfully expanded clinical-scale natural killer (NK) cells from cord blood units, adding to its existing adult peripheral blood mononuclear cell-derived therapeutics. The company intends to reorganize and streamline its group structure to create a new cord blood-derived biotech business. According to the referenced press release, this move supports an expansion into auto-immune diseases and builds on a recent cord blood bank acquisition.
FAQ
What is the current stock price of CytoMed Therapeutics (GDTC)?
What is the market cap of CytoMed Therapeutics (GDTC)?
